title: Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
abstract: Human papillomavirus (HPV) types 6, 11, 16 and 18 L1 virus-like particles (VLPs) have been used to generate the prophylactic quadrivalent vaccine, Gardasil. There is a high degree of L1 homology between HPV types and it is likely that there is a substantial degree of surface exposed viral epitope similarity. An investigation of vaccine-induced antibody binding and neutralization was undertaken focusing on A7 species members, HPV 18 and 45. Polyclonal sera from Gardasil recipients and from HPV 18 L1 VLP recipients were evaluated. Vaccine-induced antibodies were found to cross-neutralize HPV 45 pseudovirions (PsV) in vitro. Examination of a panel of monoclonal antibodies made against L1 VLPs revealed the presence of conformational, neutralizing epitopes on the surface of VLPs that may be shared between HPV 18 and HPV 45. These data demonstrate that Gardasil(r) immunization induces antibodies capable of neutralizing HPV 18 PsV and HPV 45 PsV in vitro.
authors.affiliation: Vaccine and Biologics Research, MRL, Merck & Co., Inc., West Point, Pennsylvania, USA.
authors.forename: Judith F
authors.initials: JF
authors.lastname: Smith
authors.forename: Michelle
authors.initials: M
authors.lastname: Brownlow
authors.forename: Martha
authors.initials: M
authors.lastname: Brown
authors.forename: Rose
authors.initials: R
authors.lastname: Kowalski
authors.forename: Mark T
authors.initials: MT
authors.lastname: Esser
authors.forename: Wanda
authors.initials: W
authors.lastname: Ruiz
authors.forename: Eliav
authors.initials: E
authors.lastname: Barr
authors.forename: Darron R
authors.initials: DR
authors.lastname: Brown
authors.forename: Janine T
authors.initials: JT
authors.lastname: Bryan
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology*; D000917:Antibody Formation; D036022:Capsid Proteins / Q000276:immunology*; D003429:Cross Reactions; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D052161:Human papillomavirus 18 / Q000276:immunology; D006801:Humans; D007114:Immunization; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000276:immunology*; D014771:Virion / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D036022:Capsid Proteins; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines